Background: Recurrence is a major factor leading to treatment failure and death in gastric cancer (GC) patients following surgical resection. Importantly, the prediction of recurrence is critical in improving clinical outcomes. We isolated a group of microRNAs (miRNAs) and evaluated their usefulness as prognostic markers for the recurrence of GC.
multiple essential biological functions, it is not surprising that the abnormal miRNA expression will lead to disease and even cancer [12] .
MicroRNAs have been presented as effective potential biomarkers for tracing the tissue origin in malignant tumors of unknown primary origin [13] ; miRNAs expression profiles are able to reflect the developmental lineage and differentiated state of the tumors [12] . Systematic analysis on the stability of miRNAs as well as optimized conditions for expression analysis using formalin-fixed paraffin-embedded samples have been reported previously [14] [15] [16] , shedding light on their unanticipated diagnostic potential. There are a limited number of miRNAs [17] in the human genome that are known to regulate 30% of genes [18] . These attributes of miRNAs may provide us with a simple method to predict the recurrence risk for cancer patients.
In this study, we have identified a group of miRNAs having potential to predict recurrence risk of GC. A single classifier consisting of two miRNAs was devised and validated as a molecular predictor for the recurrence risk of GC patients following curative resection.
methods clinical samples
Patients undergoing gastrectomy for potentially curable GC at the Peking University School of Oncology (Beijing Cancer Hospital and Institute) were subjects in this study. Eligibility for inclusion in this study included histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction. All patients had received complete resections including an attempt at complete tumor removal with inclusion of wide negative margins and extended retroperitoneal lymphadenectomy (D2 type). Information on clinicopathological, therapeutic and outcome parameters of patients from July 1998 to June 2005 was collected retrospectively. Cancer staging was according to the fifth edition of the American Joint Commission on Cancer TNM (tumor-node-metastasis) criteria.
Recurrence was defined as any cancer recurrence including lymph node, remnant stomach, local, peritoneal and hematogenous metastases. All patients who experienced recurrence of cancer were diagnosed clinically or radiographically, and confirmed by biopsy via upper gastrointestinal endoscope or percutaneous puncture. The radiographic standard for the recurrence diagnosis included computed tomography (CT) or magnetic resonance imaging of the chest, abdomen, pelvis, head and bone scans, or other diagnostic tests that were used only under special circumstances. All of the samples were obtained from surgical specimens of patients with gastric adenocarcinoma and all patients gave written consent for the use of these tissues for research purposes. We selected samples from 65 patients with and without GC recurrence. We obtained 42 frozen fresh and 38 paraffin-embedded samples, including 15 samples that matched both frozen fresh tissues and paraffin-embedded ones.
miRNA microarray
The miRNA microarray analysis was carried out as described in detail on the website of CapitalBio (http://www.capitalbio.com) and also according to Hua's procedure [19] . Briefly, 50-100 lg of total RNA was used to extract miRNAs using an miRNA isolation kit (Ambion, Austin, TX). Fluorescein-labeled miRNAs were used for hybridization on each miRNA microarray chip containing 509 probes in triplicate. The chips were scanned using ScanArray Express laser scanner (Packard Bioscience, Covina, CA).
Raw data were normalized using Lowess method and analyzed in GenePix Pro 4.0 software (Axon Instruments, Foster City, CA).
RNA extraction from tissues
RNA was extracted from frozen fresh GC tissues using a standard Trizol protocol (Invitrogen, Carlsbad, CA). For paraffin-embedded samples, one tissue slice (4 lm) was scraped and placed into a 1.5 ml microcentrifuge tube. Xylene (1 ml) was added for deparaffinization and followed by ethanol washes. Proteins were degraded with a proteinase K solution at 55°C overnight. The RNA was extracted with acid phenol:chloroform followed by ethanol precipitation. The RNA pellets were air-dried and dissolved in 20 ll of nuclease-free water.
real-time quantitative PCR
Mature miRNA sequences were acquired from the Sanger Institute miRBase Sequence Database (http://microrna.sanger.ac.uk/sequences/). Stem-loop reverse transcription (RT) primers were designed according to Chen [20] . The RT reaction conditions used involved incubations at 16°C for 30 min; 37°C for 30 min and then 72°C for 10 min. Quantification of differentially expressed miRNAs was conducted with an RT-Cyclerä 436 system (CapitalBio Corp., Beijing, China). The thermal cycling protocol for the PCR involved an initial denaturation step at 95°C for 5 min followed by 40 cycles at 95°C for 30 s, 57°C for 30 s and 72°C for 30 s. The melt curves for each PCR were carefully analyzed to determine any nonspecific amplification. The expression of each miRNA was calculated using the 2 2DDCT formula and normalized to U6 expression.
unsupervised algorithm
Significant analysis of microarray (SAM) [21] was used to perform the unsupervised clustering calculation. The cut-off for significance was determined by a tuning parameter delta, chosen by the user based on the false-positive rate and represented by the q value. We chose a fold change >2, and q = 0 as the selection criteria for the differential expression of miRNAs.
supervised algorithm
We used the supervised classification algorithm, k-top scoring pairs (k-TSP) [22] , to process the differential miRNA expression profile and select miRNA pairs. The basic principle of the TSP is to identify miRNA pairs that are reversal expressed in two classes. The values a, b, c and d represent the sample sizes which correspond to the classification condition and N1, N2 represent the total sample size of each class, N1 = a + b, N2 = c + d. We were able to calculate the 'Classification Score' of each gene pair (i, j) using the formula: Score ij = ja/N1 -c/N2j=jb/N1 2 d/N2j. We used 'larger' scores to select specified gene pairs (i, j). The values X i and X j represent the expressed level for each target gene. If X i < X j was observed, then the pair (i, j) belonged to class 1; if X i > X j , it was considered class 2. 
clinical characteristics of GC patients
A total of 65 patients with/without recurrence were selected for systematic analysis: 29 patients had recurring GC that was proven pathologically by biopsy at anastomosis sites via endoscopy and 36 patients without recurrence were selected as the control group with matches in sex, age at diagnosis, TNM staging, treatment and the number of involved lymph node (Table 1) .
There was no significant difference in the status of adjuvant chemotherapy between the two groups (P = 0.967), with 9 of 29 (31.1%) patients experiencing recurrence and 11 of 36 (30.5%) patients without recurrence receiving adjuvant chemotherapy. The median cycles of therapy were five in the recurring group and six in the nonrecurring group.
There was a significant difference in survival/death ratio noted (9/20 in recurrence group versus 27/9 in nonrecurrence group, P < 0.001), with median survival time of 31.5 months in recurrence versus 82.4 months in nonrecurrence group, respectively (P < 0.001), and a median survival time as 8.5 months once recurrence appeared in the patients (Table 1) .
miRNA expression profiles associated with GC recurrence
We used a miRNAs microarray chip to measure miRNAs expression levels in eight GC samples with/without recurrence (four of four) as training set. When comparing miRNA expression between the groups, 10 up-regulated and 7 downregulated miRNAs were found that were statistically significant Median survival time after recurrence (months) 8.5 / Figure 1 . Cluster analysis of expressed microRNAs (miRNAs) in gastric cancer (GC) samples with and without recurrence. A total of 17 differential expressed miRNAs, including 10 up-regulated and 7 down-regulated, were identified by significant analysis of microarray in GC samples with and without recurrence according to the criteria of FC > 2, q = 0. Columns represent samples and rows represent miRNAs (black, green and red correspond to unchanged, down-regulated and up-regulated, respectively). NR, nonrecurrent; R, recurrent.
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in the GC recurrent group (supplemental Table S1 , available at Annals of Oncology online). These 17 miRNAs could be used to discriminate between GC with and without recurrence based on a hierarchical cluster analysis ( Figure 1 ). Furthermore, we carried out real-time quantitative PCR (qPCR) analysis to validate the microarray data. We detected the relative expression levels of hsa-miR-375, hsa-miR-142-5p, hsa-miR-32, hsa-miR-19a and hsa-miR-194 in eight test samples. miRNA U6 was used as a control to calculate the relative expression level of differentially expressed miRNAs by the 2 2DDC T method [23] . The fold change was calculated by comparing the relative expression level of each miRNA in the GC recurrent and nonrecurrent groups. The fold change of this group of selected miRNAs, hsa-miR-375, hsa-miR-142-5p, hsamiR-32, hsa-miR-19a and hsa-miR-194, obtained from the microarray data were consistently confirmed by qPCR analysis (Figure 2 ).
hsa-miR-375 and hsa-miR-142-5p as a classifier to predict recurrence risk of GC The miRNA microarray data were analyzed and evaluated with supervised classification using the k-TSP method. Unlike other studies that processed the original microarray data directly by using a supervised algorithm, we first dealt with the original data using the unsupervised algorithm SAM to identify differentially expressed miRNAs and then combined these data with the supervised algorithm k-TSP to recognize miRNA pairs with a stronger affinity for classification. We obtained four classifiers that recognized the recurrence risk of GC with range from 50% to 100% sensitivity and specificity, respectively, including classifier 1 (hsa-miR-375 and hsa-miR-142-5p), classifier 2 (hsa-miR-375 and hsa-miR-296), classifier 3 (hsamiR-335 and hsa-miR-296) and classifier 4 (hsa-miR-133b and hsa-miR-296) ( Table 2) .
We further selected classifier 1, as a combination of hsa-miR-375 and hsa-miR-142-5p to improve sensitivity and specificity dramatically, to forward implication for recognizing the recurrence risk of GC. Our data showed that the AUC value of classifier 1 was 1.0, which was higher than hsa-miR-375 (0.75) or hsa-miR-142-5p (0.937) alone, respectively (Table 3) .
validation of the classifier in frozen fresh and tiny paraffin-embedded samples of GC by real-time qPCR
The expression level of each miRNA was detected by real-time qPCR and we calculated the difference in Ct value to determine which group the test samples belonged to. If the Ct (hsa-miR-142-5p) 2 Ct (hsa-miR-375) was equal to a negative number, we classified it as a nonrecurrent sample; otherwise, it was classified as a recurrent sample. We hypothesized that the larger the difference in the Ct value, there was a greater likelihood that the sample belonged to a corresponding class. The results showed that in 42 frozen fresh samples, including 8 samples that were used in microarray experiment, 5 nonrecurrent samples were misclassified ( Figure 3A ) with 89% sensitivity and 100% specificity (Table 3) . Of the 38 paraffin-embedded samples, 4 cases were misclassified into the nonrecurrent group ( Figure 3B ) with 90% sensitivity and 94% specificity (Table 3) . Importantly, we detected this classifier in 15 samples of a test set, which matched both frozen fresh and paraffin-embedded Figure 3C ). This PCR-based classification method provides a new tool with high sensitivity and specificity ( Figure 3D -E) both in frozen fresh and paraffin-embedded samples of GC. 
hsa-miR-375 and hsa-miR-142-5p as a disease progression marker to predict recurrence risk in GC patients
The 65 GC patients were divided into two groups, including 29 patients with recurrence as a group and 36 patients without recurrence as a group. The patients who experienced a recurrence of GC had a significantly reduced median survival rate (P < 0.001; Figure 4A ). We detected the expression levels of hsa-miR-375 and hsa-miR-142-5p in all 65 GC samples. Here we used hsa-miR-375 or hsa-miR-142-5p alone as a classifier to predict the prognosis of these patients; the survival analyses results show that no significant difference was observed in the two groups that included high expression of hsa-miR-375 compared with low expression of hsa-miR-375 (P = 0.07; Figure  4B ) and high expression of hsa-miR-142-5p compared with low expression of hsa-miR-142-5p (P = 0.059; Figure 4C Figure 4D ).
signaling pathway and gene ontology analyses of the classifier 1 targeted genes In order to investigate the possible regulation mechanisms of the hsa-miR-375 and hsa-miR-142-5p in the process of GC recurrence, we utilized three different databases to select plausible targets of these two miRNAs. A total of 822 (76.9%), 106 (9.9%) and 141 (13.2%) target genes of hsa-miR-375 were predicted by three databases described above, respectively. Among them, 13 (1.2%), 17 (1.6%) and 22 (2.1%) genes were original article Annals of Oncology overlapped between miRanda and PicTar, miRanda and TargetScan, PicTar and TargetScan, respectively. And a total of 737 (51.6%), 537 (37.6%) and 155(10.8%) targeted genes of hsamiR-142-5p were predicted, respectively. Seventy-one (4.9%), 29 (2%) and 54 (3.8%) genes were overlapped between miRanda and PicTar, miRanda and TargetScan, PicTar and TargetScan, respectively. Signaling pathway analyses showed that most of the targeted genes that were regulated by hsa-miR-375 and hsa-miR-142-5p were involved in the same pathways, such as cell cycle, focal adhesion, MAPK, transforming growth factor-b, Wnt and vascular endothelial growth factor (VEGF) (Tables 4 and 5) . It was also found that hsa-miR-375 was involved in the regulation of the apoptosis pathway, and hsa-miR-142-5p regulated the notch pathway (Tables 4 and 5 ). We proposed that these multiple pathway alterations might be involved in clinical pathological features and patients' outcome of GC ( Figure 5 ). Meanwhile, we used an integrated gene ontology database molecular annotation system (http://www.capitalbio.com) to annotate the molecular function of the miRNA targeted genes and another integrated database, BioRag (http://www.biorag.org), to investigate the miRNA targeted genes and their involvement in various signal pathways. The results showed that genes regulated by hsa-miR-375 and hsa-miR-142-5p both participated in most of the important biological process associated with human cancer (supplemental Tables S1 and S3 , available at Annals of Oncology online). Complicated biological process network of genes regulated by hsa-miR-375 and hsa-miR-142-5p can observed in supplemental Figure S1A and B (available at Annals of Oncology online).
discussion
Recurrence is frequent in GC patients following surgery; therefore it is important to identify cases with a high recurrence risk. Traditional clinic pathological factors are sometimes inadequate for prediction of recurrence in individuals and many research groups have attempted to identify markers using new technologies that might distinguish these high-risk cases. A number of recent investigations have documented miRNA alterations that are involved in the initiation and progression of human cancers. miRNA expression profiling of human tumors have identified expression signatures associated with diagnosis, staging, progression, prognosis and response to treatment.
In this study, we analyzed primary GC cases in order to predict disease recurrence and defined nonrecurrent cases as those free of GC for at least 1 year after curative resection. We grouped two miRNAs, hsa-miR-375 and hsa-miR-142-5p, as a classifier to predict GC recurrence. We validated this classifier on frozen fresh and paraffin-embedded tissues with >85% sensitivity and specificity. In these 65 cases, a total of 8 cases were misclassified using our miRNA classifier, including 6 cases that not recur before 2009. We referred to the clinical characteristics of these six patients again and found that two of these cases were relapsed after 4 years in 2009 (both from 2005 to 2009); one case was diagnosed as hematogenous and lymph metastasis after curative resection (from 2003 to 2005). The survival analyses results showed that patients with high expression levels of hsa-miR-375 and low expression levels of hsa-miR-142-5p had reduced overall survival rate compared with those with low expression levels of hsa-miR-375 and high expression levels of hsa-miR-142-5p. These results indicate that this classifier had the potential to predict recurrence of GC.
Microarray technology has developed significantly and become a comprehensive and useful method to help us better understands cancers [24] . It is now widely used to study the functional roles of miRNAs in many types of cancer [9, 25] , with several significant miRNA effects on oncogenes and tumor suppressor genes identified. Of the 17 miRNAs identified in this study, hsa-miR-373 was one of the down-regulated miRNAs in the recurrent group. This may be an oncogene functioning through the well-known p53 pathway that is involved in carcinogenesis [26] . Some miRNAs, such as hsa-miR-19a and hsa-miR-32, are located in cancer-associated genomic regions, which might be involved in malignancies via deletion, amplification or epigenetic modification mechanisms [27] . Additionally, hsa-miR-200b and hsa-miR-429 were both upregulated in recurrent cases and clustered on chromosome 1, confirming that some miRNAs are clustered and able to coregulate their targeted genes [28] . Until now, the two miRNAs designated in this study as the classifier to predict the risk of GC recurrence have not been well characterized. The miRNA, hsa-miR-375, was restricted to mouse pancreatic islets, MIN6 and TC1 cells [29] . This pancreatic-specific miRNA directly targets PDK1 and is known to play key roles in glucose regulation of insulin gene expression and b-cell growth [29, 30] . The hsa-miR-142-5p gene is located on chromosome 17 at a site of known translocation associated with an aggressive B-cell leukemia [31] that has been shown to be highly expressed in murine hematopoietic organs [32] . Ectopic expression of hsa-miR-142-5p had no profound effect on B lymphoid lineage, whereas it substantially altered differentiation in the T lymphoid lineage [32] . The reason why hsa-miR-375 is always expressed at a higher level than hsa-miR-142-5p in the recurrent group and with the opposite occurring in the nonrecurrent group remains unknown. It is possible that miRNAs are key regulators in GC and this specific abnormal miRNA expression pattern could lead to events that select for progression, causing patients to relapse. Thus, we identified recurrence-associated miRNA targeted genes and found that targeted genes regulated by hsa-miR-375 and hsa-miR-142-5p were involved in most of the same oncogenic signaling pathways, such as cell cycle, cell proliferation, MAPK, Wnt and VEGF. However, p53 signal pathway was regulated by hsa-miR-375 but not by hsa-miR-142-5p. And we have confirmed that p53 was down-regulated in the GC cell line AGS that overexpressed hsa-miR-375 (data not shown). These multiple signal pathway alterations, especially including p53 pathway, might reasonably affect clinical outcome including GC recurrence risk [33] .
Archived paraffin-embedded specimens are one of the most readily available materials in hospitals, which are often kept with well-documented clinicopathological data. They represent excellent sources for prognostic application in both basic research and clinical studies. miRNAs range in size from 19 to 25 nt and they are protected by the RNA-induced silencing complex, which may render them less susceptible to RNA degradation compared with mRNA in these tissues [34] . Thus, we were able to detect miRNA expression in paraffin-embedded samples and focused on the systematic analysis using our classifier paradigm to accurately evaluate them for relevant prognostic value. Our data indicate that this two-miRNA classifier has significant potential application in the prediction of GC recurrence with high sensitivity and specificity. This PCR-based classification method, therefore, appears to provide us with a way, using easily available clinical specimens, to predict disease recurrence.
In summary, we have identified a two-miRNA classifier that can predict recurrence risk of GC patients. By combining this classifier with conventional clinicopathological factors, we should be able to predict a patient's disease outcome more accurately. Additionally, the identification of high-risk patients would lead to the consideration of additional therapeutic intervention and may thus inform the physician of a better follow-up program.
